Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting

Rizzo, Manglio; Bluthgen, María; Recondo, Gonzálo; Naveira, M.; Perfetti, A.; Rizzi, F.; Kuzminin, A.; Faura, Victoria; Cerini, M.; Videla, Alejandro J.; Silva, Carlos; Lupinacci, L.; Minatta, N.

doi:10.1007/s10147-021-01896-x

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 2021 Japanese Lung Cancer Society Guidelines for Diagnosis and Treatment of Lung Cancer do not currently support the use of ICIs in patients with a low PS score. The study by Rizzo et al highlights that a decline in PS correlates with decreased progression-free survival (PFS) and overall survival (OS) in patients with a PS of up to 2 [ 15 ]. Nevertheless, the research does not conduct an extensive analysis of PS concerning specific mutations, such as SMARCA4.…”

Section: Discussionmentioning

confidence: 99%

Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)

Koizumi¹,

Tamura²,

Yoshida³

et al. 2023

Cureus

View full text Add to dashboard Cite

SWItch/Sucrose Non-Fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4) mutations are commonly reported in non-small cell lung cancer (NSCLC) and are associated with a poor prognosis. There is insufficient evidence regarding the efficacy of immune checkpoint inhibitors (ICIs) in SMARCA4-deficient NSCLC patients with poor performance status (PS). We report two cases of advanced SMARCA4-deficient NSCLC treated with ICIs, in which marked regression of the tumor and improved general condition of the patients were achieved.

show abstract

Section: Discussionmentioning

confidence: 99%

Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)

Koizumi¹,

Tamura²,

Yoshida³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…We agree with that conclusion, which has been supported by several other studies. [2][3][4][5] Instead, we believe the most relevant question to be asked is whether patients with poor performance status derive clinical benefit from an ICI. Unfortunately, with a lack of randomized placebo-controlled prospective clinical trials that include patients with an ECOG PS of 2 or higher, this question is difficult to answer.…”

mentioning

confidence: 99%

Reply to A.R. Khaki et al

Ramnaraign

2021

JCO Oncology Practice

View full text Add to dashboard Cite

We thank the authors Khaki et al 1 for their well-written and poignant editorial on our review "Immunotherapy management in special cancer patient populations" published in JCO Oncology Practice earlier this year. We appreciate the fact that the authors have also concluded that immune checkpoint inhibitors (ICIs) are likely safe and effective for the special cancer patient populations that are commonly excluded from clinical trials; however, they have expressed reservations for patients with poor performance status.

show abstract

Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting

Cited by 2 publications

References 31 publications

Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)

Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)

Reply to A.R. Khaki et al

Contact Info

Product

Resources

About